C O M M U
N I T Y A L
E R T -- D R
U G P
R I C I N G
Spare the Protease but
Keep the Price?
Please consider having your organization sign
onto the attached Consensus Statement. It concerns the eventual
price of two new potent drugs: the nucleoside analog abacavir
(Ziagen) and the nNRTI efavirenz (Sustiva). Both of these compounds
are under FDA review and no doubt will soon enter the market.
There has been considerable speculation that either or both will
be priced far higher than other nukes and nNRTIs, perhaps even
in the range of the protease inhibitors that they would supplement
or sometimes replace. Such a move would substantially increase
the cost of health care for a great number of people with HIV.
The ability of public programs such as ADAP and Medicaid to support
HIV treatment would be further limited, and even private HMOs
may object to prescribing these new drugs. We need to send a loud,
clear and united message immediately before final pricing decisions
are made by the sponsors, Dupont Pharma and Glaxo Wellcome.
We hope that this statement becomes the first
step in a wider campaign over the cost of HIV treatments to be
directed at all sponsors. Some companies in the past year have
quietly raised prices on drugs that already bore high price tags,
without strong protest from the HIV-affected community. There
is no justification for these increases other than "what
the market will bear." But as combination regimens become
ever more elaborate, people with HIV as well as their third-party
payers will likely face medical costs over the course of a lifetime
rising into the stratosphere. The pharmaceutical industry, meanwhile,
stands to reap a windfall. Companies have less justification for
squeezing high short-term profits from their drugs since people
will be using them for longer periods of time. Make no mistake
about it -- each unfair pricing action cuts off the lifeline of
treatment for another portion of the population!
Please join with us in putting this urgent
issue on the front burner of AIDS activism and support our efforts
by asking your agency or organization to sign-on to the attached
consensus statement now. Also, please watch for further communiquÈs
on this important issue.
Time is of the essence! To endorse the attached
consensus statement, please reply ASAP to::
fax: 310/471-4565
e-mail: Linda_Grinberg@prodigy.com
FAIR PRICE WORKING GROUP
Martin Delaney, Project Inform; Dave Gilden,
GMHC/Gay Men's Health Crisis; Ron Baker, San Francisco AIDS Foundation;
Linda Grinberg, FAIR/Foundation for AIDS & Immune Research;
Bill Bahlman, ACT UP New York; John James, AIDS Treatment News
Consensus Statement on the
Pricing of Abacavir and Efavirenz
We, the undersigned, have grave concerns regarding
the overall cost of therapy for HIV disease. While we are heartened
by the progress made in moving toward simpler, easier to use regimens,
we are dismayed by the possibility that prices of new drugs in
the nucleoside and non-nucleoside RT inhibitor class might be
similar to those of protease inhibitors, rather than other drugs
in their own respective classes. Such inappropriate pricing will
quickly outweigh any possible added benefits of new drugs like
(Ziagen) and efavirenz (Sustiva). As drugs become available which
might facilitate better adherence and possibly more durable long-term
treatment, manufacturers should be planning to lower the daily
cost of their regimens, not increase them. The long-term survival
afforded by the present generation of therapies makes it possible
for manufacturers to set lower, or at lest stable prices, and
still have adequate incentive to reinvest in continued development
of HIV/AIDS drugs. Recently cited reductions in the overall cost
of health care for HIV infected people will almost certainly be
reversed in coming years if manufacturers continue to increase
or maintain current pricing levels.
We are in a new era in the treatment of HIV
disease and rethinking drug pricing which reflects this changing
reality is long overdue.
To the best of our knowledge, the development
costs of these drugs were not comparable to those of the first
protease inhibitors, nor is on-going cost of product as high.
Quite the contrary, because of the efficiency of the new drugs,
far fewer pills and thus much less physical product is required
for dosing on a daily basis. Similarly, there has been nothing
extraordinary about the cost of clinical trials required to bring
these drugs to market.
Abacavir and efavirenz are likely to be used
by both treatment naive and treatment experienced patient populations,
making their potential market very large. If the prices are high
and either or both drugs used in naive populations in place of
existing drugs, the overall cost of therapy will go up. An even
greater cost penalty will occur for treatment experienced patients,
who are likely to use both drugs together, often in combination
with a protease inhibitor. This would lead to an unacceptably
high cost of therapy. We cannot stand idly by while the price
of living with HIV disease escalates so rapidly.
State ADAP programs have limited amounts of
money allocated to them each year. Many of the state's annualized
programs are bankrupt prior to fiscal year-end. Some state ADAP
and Medicaid programs have removed vital medications to prevent
and treat opportunistic infections from their formularies. State
ADAP and Medicaid programs are under close scrutiny by governmental
panels in order to cut costs.
The price of one drug can affect the availability
of other medications. Increasingly, this same sad scenario is
beginning to affect the availability of drugs within HMO settings.
The price of these drugs will have a pervasive impact on the overall
quality of care people with HIV/AIDS receive in this country.
The sponsors of abacavir and efavirenz have
both expressed a strong desire to create goodwill and cooperative
working relationships with the community. No one wants to see
those relationships jeopardized or eroded over this issue, but
that surely will happen if pricing is inappropriate. As we face
another round of price setting, industry must recognize this is
an issue that is now moving to the forefront. Exploitative pricing
will trigger widespread hostility, contentious debate and closer
scrutiny of industry practices in general. This will have far
reaching consequences. Have DuPont Pharma and Glaxo Wellcome considered
the possible repercussions of opening this Pandoraís box?
Are you willing to risk the aftermath of ill will within the community
and to be held accountable within industry?
Therefore, we must clearly state for the record
that the only acceptable
prices for these drugs must be in accordance with other drugs
of their respective classes. (*See
amended consensus statement attached as Addendum.) We urge manufacturers to immediately begin a dialogue
with the community about this pricing issue and not presume it
can simply announce a price immediately prior to regulatory approval,
without consequences, as a fait accompli.
____________________________________ ________________________________
Signature ___________ Name of Organization (print legibly)
*Addendum:
ACT UP/NY could not sign on to a statement
that labeled a price of $3,100 a year as "acceptable."
We changed one sentence wording:
"These drugs must be
priced no higher, and preferrably much lower, than drugs of their
respective classes."
ORGANIZATIONAL ENDORSEMENTS
- 1. ACT UP BOSTON, BOSTON, MA
- 2. ACT UP GOLDEN GATE, CA
- 3. ACT UP EAST BAY, CA
- 4. ACT UP PHILADELPHIA, PHILADELPHIA, PA
- 5. ACT UP NEW YORK, NY*
- 6. ACTIONS TRAITEMENTS, PARIS, FRANCE
- 7. AIDS ADVOCACY ALLIANCE, HONG KONG, CHINA
- 8. AIDS ACTION, WASHINGTON, D.C.
- 9. AIDS CARE, INC., VENTURA, CA
- 10. AIDS COALITION OF CHATAUQUA COUNTY, NY
- 11. AIDS COMMUNITY NETWORK
- 12. AEGIS/AIDS EDUCATION GLOBAL INFORMATION
SERVICES, CA
- 13. AIDS LAW PROJECT OF PENNSYLVANIA, PHILADELPHIA,
PA
- 14. AIDS, MEDICINE & MIRACLES, BOULDER,
CO
- 15. AIDS NETWORK, WEST VIRGINIA
- 16. APLA/AIDS PROJECT LOS ANGELES, CA
- 17. AIDS RESEARCH ALLIANCE, LOS ANGELES,
CA
- 18. AIDS SERVICES OF DALLAS, TX
- 19. AIDS TREATMENT CENTRE, PRETORIA, SOUTH
AFRICA
- 20. AIDS TREATMENT INITIATIVES, ATLANTA,
GA
- 21. AIDS TREATMENT NEWS, CA
- 22. AIDS TREATMENT DATA NETWORK, NY
- 23. AIDS WASTING FOUNDATION
- 24. AMERICAN SOCIAL HEALTH ASSOCIATION, RESEARCH
TRIANGLE PARK, NC
- 25. ANDREW ZIEGLER FOUNDATION
- 26. AUSTRALIAN FEDERATION OF AIDS, TREATMENT
OFFICERS NETWORK, which represent all States and Territories
of Australia
- 27. BEING ALIVE: PEOPLE WITH HIV/AIDS ACTION
COALITION OF LOS ANGELES, CA
- 28. BELLE REVE, NEW ORLEANS, LA
- 29. BLUE RIDGE PWA EMPOWERMENT PROJECT, ASHEVILLE,
NC
- 30. BODY POSITIVE NORTH WEST, UNITED KINGDOM
- 31. CANADIAN TREATMENT ADVOCATES COUNCIL,
TORONTO, ONTARIO, CANADA
- 32. CARETEAM, MYRTLE BEACH, SC
- 33. CENTER FOR AIDS RESEARCH, NY
- 34. CHARLOTTE HIV/AIDS NETWORK, INC.
- 35. CHC/THE CORRECTIONAL HIV CONSORTIUM
- 36. CHICAGO ADULT ACTG CAB/COMMUNITY ADVISORY
BOARD, CHICAGO, IL
- 37. COASTAL AIDS NETWORK, BELFAST, ME
- 38. COCD-SIDA, QUEBEC, CANADA
- 39. COMMUNITY ADVISORY BOARD, AACTG, HAWAII
- 40. COMMUNITY OUTREACH INTERVENTION PROJECTS,
CHICAGO, IL
- 41. COMMUNITY PRESCRIPTION SERVICE, INC.,
NY
- 42. COMMUNITY PROGRAMS FOR CLINICAL RESEARCH
ON AIDS STATISTICAL CENTER,COORDINATING CENTER FOR BIOMETRIC
RESEARCH, DIVISION OF BIOSTATISTICS, SCHOOL OF PUBLIC HEALTH,
UNIV. OF MINNESOTA, MINNEAPOLIS, MN
- 43. COORDINADORA NACIONAL DE PERSONAS VIVIENDO
CON VIH/SIDA, CHILE
- 44. (National Coordinating Committee of People
Living with HIV/AIDS, Chile)
- 45. CORPORACION CHILENA DE PREVENCION DEL
SIDA, SANTIAGO, CHILE
- 46. CPCRA CAB, SAN FRANCISCO, CA
- 47. CRITICAL PATH AIDS PROJECT, PHILADELPHIA,
PA
- 48. FAIR/FOUNDATION FOR AIDS & IMMUNE
RESEARCH, CA
- 49. GMHC/GAY MENS HEALTH CRISIS, NY
- 50. GTT/GRUPO DE TRABAJO SOBRE TRATAMIENTOS
DEL VIH, BARCELONA, SPAIN
- 51. HARVARD/BOSTON MEDICAL CENTER AIDS CLINICAL
TRIALS UNIT, ACTG COMMUNITY ADVISORY BOARD
- 52. HIVCARE & CLINICAL RESEARCH, SAINT
FRANCIS MEMORIAL HOSPITAL, S.F. , CA
- 53. HIV NACHRICHTEN, GERMANY
- 54. HOLISTIC HEALTH CENTER
- 55. HOPE FOR THE PEE DEE
- 56. HYACINTH AIDS FOUNDATION OF NEW JERSEY,
NJ
- 57. IAPAC/INTERNATIONAL ASSOCIATION OF PHYSICIANS
IN AIDS CARE, CHICAGO, IL
- 58. JOINT RESEARCH SERVICES, NAIROBI, KENYA
- 59. LIGHTHOUSE GROUP, ASHEVILLE, NC
- 60. LOWELL COMMUNITY HEALTH CENTER, LOWELL,
MA
- 61. NAM PUBLICATIONS, UNITED KINGDOM
- 62. NATAP/NATIONAL AIDS TREATMENT ADVOCACY
PROJECT, NY
- 63. NMAC/NATIONAL MINORITY AIDS COUNCIL,
WA
- 64. NEW ORLEANS CENTER FOR LIVING, NEW ORLEANS,
LA
- 65. NEW YORK PEER AIDS EDUCATION COALITION
- 66. OLYMPIC COMMUNITY HEALTH ASSOCIATES,
PORT ANGELES, WA
- 67. PECOS VALLEY HIV/AIDS RESOURCE CENTER,
ROSWELL, NM
- 68. PEDIATRIC CCU OF THE PACTG
- 69. PLWHA/PEOPLE LIVING WITH HIV/AIDS, VICTORIA,
AUSTRALIA
- 70. PHOENIX BODY POSITIVE, PHOENIX, AZ
- 71. POZ MAGAZINE, NEW YORK, NY
- 72. PROJECT INFORM, SAN FRANCISCO, CA
- 73. PROVINCETOWN POSITIVE PEOPLE WITH AIDS
COALITION, MA
- 74. PWA HEALTH GROUP, NY
- 75. RESEARCH SANCTUARY, CA
- 76. REGIONAL ACTG COMMUNITY ADVISORY BOARD,
CHICAGO, ILLINOIS
- 77. RYAN WHITE CENTER, LITTLE ROCK, ARKANSAS
- 78. RYAN WHITE PLANNING COUNCIL, DC
- 79. SAN FRANCISCO AIDS FOUNDATION, SAN FRANCISCO,
CA
- 80. SAN JOAQUIN AIDS FOUNDATION, THE STAFF
OF, STOCKTON, CA
- 81. SEARCH FOR A CURE, BOSTON, MA
- 82. SISTERS OF ST. ELIZABETH OF HUNGARY,
CA
- 83. STEP/SEATTLE TREATMENT EDUCATION PROJECT,
SEATTLE, WA
- 84. SWAA INTERNATIONAL, DAKAR, SENEGAL
- 85. SWAA/SOCIETY FOR WOMEN IN AIDS IN AFRICA
- 86. SOUTHERN TIER AIDS PROGRAM, NY
- 87. TAG/TREATMENT ACTION GROUP, NY
- 88. TERTULIA, GUATEMALA CITY, GUATEMALA
- 89. TEXAS AIDS NETWORK, TX
- 90. TITLE II COMMUNITY AIDS NATIONAL NETWORK,
WASHINGTON, DC
- 91. UNION POSITIVA, INC., MIAMI, FL
- 92. UNITED SERVICES FOR AIDS FOUNDATION,
NEW ORLEANS, LA
- 93. UNIV. OF CALIFORNIA, SAN DIEGO ACTU CAB/COMMUNITY
ADVISORY BOARD, CA
- 94. UNIV. OF PUERTO RICO, SCHOOL OF MEDICINE,
ADULTS ACTU-SITE 5401, SAN JUAN, PUERTO RICO
- 95. ìUîCAN/UPPER CAPE AIDS NETWORK,
WAQUOIT, MA
- 96. VICTORIAN AIDS COUNCIL, MELBOURNE, AUSTRALIA
- 97. WE THE PEOPLE, PHILADEPHIA, PA
- 98. WELLNESS CENTER OF SOUTH FLORIDA, FL
- 99. WESTERN NORTH CAROLINA HIV/AIDS CONSORTIUM,
ASHEVILLE, NC
- 100. WNC POSITIVE LIVING NEWS, NC
- 101. WOMEN ALIVE COALITION, LOS ANGELES,
CA, OAKLAND, CA
INDIVIDUAL ENDORSEMENTS:
- 1. Moises Agosto, Dir.Treatment Advocacy,
NMAC/National Minority AIDS Council, Washington DC
- 2. Michael Ahern, San Francisco, CA
- 3. Ernie Alexander, PLWA, Roswell, New Mexico
4. Laura E. Asturias, Editor, Tertulia, Guatemala City, GUATEMALA
5. Bill Bahlman, Founding Member, ACT UP New York, NY 6. Mark
W. Baker, Provincetown Positive/PWA Coalition, MA 7. Ron Baker,
Ph.D., Director of Treatment Advocacy, San Francisco AIDS Foundation,
CA
- 8. Elisabeth Benga-De, M.D., SWAA International,
Program Officer, Dakar. SENEGAL
- 9. Dr. Ezio Baraldi, AIDS Treatment Centre,
Pretoria, SOUTH AFRICA 10. Irl Barefield, Director, HIVCare &
Clinical Research, Saint Francis Memorial Hospital, SF, CA
- 11. Stephen J. Barksby, Body Positive North
West, United Kingdom 12. Joel Beard, aidsinfonyc.org, NY
- 13. Jorge Beloqui, GIV, S"o Paulo, BRAZIL
14. Jeanne Bergman, Ph.D., New York Peer AIDS Education Coalition
15. Louise Binder, Co-Chair, Canadian Treatment Advocates Council,
CTAC, Toronto, ONT, CANADA
- 16. B. Blevins, Wilmington, North Carolina
17. Jeff Bloom, Title II Community AIDS National Network, Washington,
DC
- 18. Mark Bowers, Education Director, Andrew
Ziegler Foundation & Education & Outreach, St. Francis
Hospital, SF, CA 19. Diane Brown, Southern Tier AIDS Program,
NY 20. Gregory S. Britt, CEO, AIDS Research Alliance, Los Angeles,
CA 21. Sally Brookins, Colorado Springs, CO 22. Nicholas Brookins,
Colorado Springs, CO 23. Robert J. Brunet PLWA Knoxville TN
- 24. Michael BuitrÛn, Center for Behavioral
Research & Services 25. Carola Burroughs, AIDS Wasting Foundation
26. Paul Buzzell, San Francisco, CA
- 27. Jill Cadman, Associate Editor, GMHCís
Treatment Issues, NY 28. Rob Capone, Exec. Director, We The People,
Philadelphia, PA 29. George M. Carter, Director, Treatment Information
Development, DAAIR, NY
- 30. Thomas E. Casey, Atlanta GA
- 31. Ben Cheng, Project Inform, San Francisco,
CA 32. Pablo Colon, Director Treatment Education & Advocacy,
GMHC, NY 33. Brian Coppedge, STEP/Seattle Treatment Education
Project, Seattle,
- WA
- 34. Jim Corti, Research Sanctuary, Los Angeles,
CA 35. Myron C. Crider, Morrow, Georgia, USA 36. Robert Dal Porto,
President, Board of Directors, Being Alive: People with HIV/AIDS
Action Coalition, Los Angeles, CA 37. Julie Davids, Director
of Education , Project TEACH & Philadelphia FIGHT, Philadelphia,
PA
- 38. Paul Davis, ACT UP Philadelphia, PA
- 39. John Daye, PLWHA/People Living with HIV/AIDS,
Victoria, AUSTRALIA
- 40. Carolyn DeAngelis, PLWA, Volunteer Speaker,
East Brunswick, NJ 41. Larry Dearman, Case Manager, Ryan White
Center, Little Rock, AK 42. Martin Delaney, Founding Director,
Project Inform, CA 43. Joseph D. DeMaria, Ocean, NJ
- 44. Daniel J. DeNoon, Senior Editor, AIDS
Weekly Plus 45. Michael Donnelly, ACT UP Golden Gate, San Francisco,
CA 46. Steven Dornbusch, Los Angeles, CA
- 47. Robert L. Drake, Cleveland, OH
- 48. Earl Driscoll, ACT UP Philadelphia, PA
49. Jerry A. Edwards, MPH, Immediate Past President & Board
Member, Western NC HIV/AIDS Consortium, Inc., Asheville, NC 50.
Kathy Edwards, Co-Chair, CAB-AACTG-Hawaii 51. Ferd Eggan, AIDS
Coordinator, City of Los Angeles, CA 52. Roberta Eidman,Triple
Hayz Corporation, Los Angeles, CA 53. Sister Mary Elizabeth,
AIDS Education Global Information System (AEGIS), CA
- 54. Anna Forbes, MSS, AIDS and Women's Health
Policy Consultant, Philadelphia, PA
- 55. Daniel Forest
- 56. Tim Frasca, Corporacion Chilena de Prevencion
del Sida, Santiago, Chile
- 57. Brian Feit, Chair, Pediatric CCU of the
PACTG 58. Nan Feyler, Esq. Executive Director, AIDS Law Project
of Pennsylvania, Philadelphia PA
- 59. Colatta Porter-Field, Myrtle Beach, SC
60. Vernella French, United Services for AIDS Foundation, New
Orleans LA
- 61. Ruben Gamundi, Treatment Coordinator,
APLA/AIDS Project, Los Angeles, CA
- 62. Debbie Garlock, PLWA, AIP/AIDS Intervention
Project, Altoona PA & FAAN/Franklin Area AIDS Network, Chambersburg
Pa 63. Gregory J. Garlock, AIP/AIDS Intervention Project, Altoona,
PA
- & FAAN/Franklin Area AIDS Network, Chambersburg
Pa 64. Alfred L. Gaspar
- 65. Jacques Gelman, President, COCD-SIDA,
Quebec, Canada 66. Stephen Gendin, President, Community Prescription
Svcs., Exec. VP. , POZ, NY
- 67. Jeff Getty, ACT UP Golden Gate, San Francisco,
CA 68. Ian C. Gibson-Smith, AIDS Network, West Virginia 69. Dave
Gilden, Editor, GMHCís Treatment Issues. New York, NY
70. Susan Goggans, Director Client Svcs., Ryan White Center,
Little Rock, AK
- 71. Steve Goodson, ìa concerned care
providerî 72. Robert Goslin, Resource Education Coord.,
The New Orleans Center for Living, New Orleans, LA
- 73. William Greene, Board Member & Community
Advocate, AIDS Care, Inc. , Ventura, CA
- 74. Linda Grinberg, Pres.,FAIR/Foundation
for AIDS & Immune Research, Project Inform Board, CA
- 75. Jeff Gustavson, ACT UP Golden Gate, San
Francisco, CA 76. Michael Haggerty, MPH, Executive Director,
CHC/The Correctional HIV Consortium
- 77. Bridget Haire, PLWHA/People Living with
HIV/AIDS, Victoria, AUSTRALIA
- 78. Mark E. Hammann, Western North Carolina
HIV/AIDS Consortium, NC 79. Lisa Harewood, Study Coordinator,
Center for AIDS Research, NY 80. Agnes Harley, Philadelphia FIGHT,
Project TEACH & ACT UP Philadelphia, PA
- 81. Mark Harrington, Treatment Action Group,
New York, NY 82. William T. Healy, Member, Ryan White Oversight
Committee, Hawaii 83. Sharon Sharon Henkel, Polio Network, St.
Louis, Missouri 84. Sharon Hiers, Careteam, Inc, Myrtle Beach,
NC. 85. Deena Hilton, Hope for the Pee Dee
- 86. Thomas A. Hemmingsen, Chicago Adult ACTG
CAB, Chicago, IL 87. Mark J. Hoffman, Treatment Advocate, Phoenix
Body Positive, Phoenix, AZ
- 88. Tom Hofstad, San Joaquin Aids Foundation,
Tracy, CA 89. Carlton Hogan, Community Programs for Clinical
Research on AIDS Statistical Center,
- Coordinating Center for Biometric Research,
Division of Biostatistics, School of Public Health
- University of Minnesota, Minneapolis, MN
90. Robert Hutnick, PLWA, East Brunswick, NJ 91. John Iverson,
ACT UP East Bay, Oakland, CA 92. Jeff Jacobs, AIDS Action, Washington,
DC 93. Lawrence Eli Jaffe
- 94. John S. James, Publisher, AIDS Treatment
News, San Francisco, CA 95. Richard Jefferys, Access Project
Director, AIDS Treatment Data Network, NY
- 96. Charles Johns, UCAN/Upper Cape AIDS Network,
Waquoit, MA 97. Cleve Jones, Founder, The Names Project AIDS
Memorial Quilt, San Francisco, CA
- 98. Loren Jones, Clinical Trials Peer Advocate,
W.O.R.L.D., Oakland, CA
- 99. Benson Okall Jowi, Coordinator, Joint
Research Services, Nairobi, KENYA
- 100. Paul Akio Kawata, Executive Director,
NMAC/National Minority AIDS Council, Washington, DC
- 101. Jeff Kimbro, Executive Director, Careteam,
Inc., Myrtle Beach, SC
- 102. David Kiviaho, Program Director, Belle
Reve, New Orleans, LA 103. Colin Kovacs, FRCP, Toronto, CANADA
104. Kiyoshi Kuromiya, Critical Path AIDS Project, Philadelphia,
PA 105. Renee Lambert, Hope for The Pee Dee, Case Manager, Florence,
SC 106. Lark Lands, Science Editor, POZ Magazine, New York, NY
107. Garrett R. Lanzy, Endicott, NY
- 108. James Learned, PWA Health Group, New
York, NY 109. Stephen LeBlanc, ACT UP Golden Gate, San Francisco,
CA 110. Brenda Lein, Project Inform, San Francisco, CA 111. Jules
Levin, National AIDS Treatment Advocacy Project, NY 112. Nancy
MacNeil, Women Alive Coalition, Los Angeles, CA 113. Thomas L.
Magee, MD, Los Angeles, CA 114. Lana J. Roston-Mahoney, RN, BS,
Olympic Community Health Associates, Port Angeles, WA
- 115. Naisiadet Maina, Vice President, SWAA,
Society of Women and AIDS in Africa, Dakar, SENEGAL
- 116. Tran Pierre Maldonado, LK, Univ. of
Puerto Rico, Adults ACTU Site 5401,
- San Juan, PUERTO RICO
- 117. Patricia Manning, Brentwood, CA
- 118. Axel Torres Marrero, Director of Public
Policy & Legal Services, Hyacinth AIDS Foundation
- of New Jersey, NJ
- 119. Thomas G. Martin, Ryan White Planning
Council, DC EMA, Washington, DC
- 120. Tony Maynard, Treatments Officer, Victorian
AIDS Council, Melbourne, AUSTRALIA
- 121. Bob McCormick, Director HIV Dept., Lowell
Community Health Center, Lowell, MA
- & ACTG Community Advisory Board, Harvard/Boston
Medical Center AIDS
- Clinical Trials Unit
- 122. David Melendez, Humanist Movement
- 123. Virgil Rang Moler, Univ. of Puerto Rico,
Adults ACTU Site 5401, San Juan, PUERTO RICO
- 124. Eileen Monaghan, member Pediatric CCG,
Brockport, NY 125. Michael J. Monaghan, Maxís Dad, Father
of HIV boy, 10 yrs. old 126. Jacqueline Montero
- 127. Don Morrison, CEO, AIDS Services of
Dallas, TX 128. Bob Munk, RJM Ph.D.
- 129. Augustus Nasmith, Jr., President, Board
of Directors, AIDS, Medicine & Miracles, VT
- 130. Colin Nee, Director, NAM Publications,
United Kingdom 131. Steven Nesselroth, AIDS in Prison Director,The
Osborne Association, New York, NY
- 132. Lisa Newton, Careteam, Myrtle Beach,
SC 133. Layne Nichols, R.N., PWA
- 134. David Nicklin M.D., Medical Director,
Penn Family Care, Presbyterian Hospital, Philadelphia, PA
- 135. Eduardo Noriega, Union Positiva, Inc.,
Miami, FL 136. Kevin P. Nuttall, Director, Lighthouse Group,
Asheville, NC 137. Lawrence G. Olszewski
- 138. Lawrence Ouellet, Community Outreach
Intervention Projects, Chicago, IL
- 139. John Pappas, AIDS Community Network
140. Carolyn A. Parker, Ph.D., Texas AIDS Network, TX 141. Roscoe
E. Parker, WNC Aids Project, NC 142. Jane Peranteau, Executive
Director, Pecos Valley HIV/AIDS Resource Center, Roswell, NM
- 143. Dr. Stu Peller, Holistic Health Center
144. Marjorie Percival, Coastal AIDS Network, Belfast, ME 145.
Michael J. Pugh, American Social Health Association, RTP, NC
146. Gary Pujol, Executive Director, AIDS Treatment Initiatives,
Atlanta, GA
- 147. Myron Dean Quon, Staff Attorney, Western
Regional Office, Lambda Legal Defense and Education Fund, Inc.,
Los Angeles, CA 148. Virginia Ramirez, Coordinator, Univ. of
Puerto Rico Medical School, Adults ACTU-Site 5401, San Juan,
PUERTO RICO 149. Claire Rappoport, Chair, CPCRA CAB, San Francisco,
CA 150. Xavier Rey-Coquais, Actions Traitements, Paris, FRANCE
151. Iling Roeg, P.R., Univ. of Puerto Rico Medical School, Adults
ACTU-Site 5401, San Juan, PUERTO RICO (signature illegible) 152.
Leopoldo Robles, LRA, CAB Member, Univ. of Puerto Rico, Adults
ACTU-Site 540l, San Juan, PUERTO RICO
- 153. James Rosen, Citizen, Nyack, NY
- 154. Walt Senterfitt, Adv.Chair and BD. Member,
Being Alive/Los Angeles & Chief HIV Prevention Epidemiologist,
- LA County Member, California Prevention Planning
Working Group
- 155. Carey Sharpe, Case Manager, Careteam,
Myrtle Beach, SC 156. Jeffrey Schouten, Member ACTG Community
Consortium (CCG), STEP/Seattle Tx. Educ. Project
- 157. David Scondras, Search for a Cure; Boston
158. Kelly Scott, Seattle, WA
- 159. Matthew Sharp, ACT UP Golden Gate, S.F.
CA 160. Stephen Skuce, Treasurer, ACT UP Boston , Boston, MA
161. Clint Spencer, Co-Chair, CAB-AACTG-Hawaii 162. Sean Strub,
Founder, POZ Magazine, NY 163. Joan Tallada, GTT/Grupo de Trabajo
Sobre Tratamientos Del VIH, Barcelona, SPAIN
- 164. Mark Tangard
- 165. Heidi Taubenfeld, Wellness Center of
South Florida 166. Jeff Taylor, Chair, University of California,
San Diego ACTU Community Advisory Board
- 167. David L Thomas, Chairman, Regional ACTG
CAB, Chicago,IL 168. Joe Thomas, AIDS Advocacy Alliance, Hong
Kong, China 169. Russ Tilaro, AIDS Coalition of Chatauqua County,
Falconer, NY 170. Martha Underwood, Westat, Inc.
- 171. Ulrich Wuerdemann, Editor, HIV Nachrichten,
Germany 172. Rick Vance, MHA, Community Prescription Services,
NY 173. Marilyn Vargas, Univ. of Puerto Rico, Adults ACTU Site
5401, San Juan, PUERTO RICO
- 174. Enid Vazquez, Associate Editor, Positively
Aware, Chicago, IL 175. James P. Vokoun, President, The Colt
45's , Houston, TX 176. Jeff W. White, Asheville, NC - individual
177. David P. Wilson, Executive Director, The Charlotte HIV/AIDS
Network Inc.
- 178. Hazel Wilson, AIDS Community Network
179. Robert C. White, St. Louis, Missouri 180. Mrs. Eka Williams,
President, Society for Women and AIDS in AFRICA
- 181. Jerry Williamson
- 182. Ulrich Wuerdemann, Editor, HIV Nachrichten,
Germany 183. Jose Zuniga, Deputy Director, IAPAC/Intíl.
Assoc. of Physicians in AIDS Care, Chicago, IL
September 9, 1998
use back button on browser to return
See also:
Dupont ACTION